The influence of primary tumor site on the prognosis of breast cancer is not consistent but still controversial. We analyzed data of 63,388 patients with primary breast cancer from the Korean Breast Cancer Registry. Lower inner quadrant showed a worse prognosis despite having more favorable clinicopathologic features than other tumor locations and it was more prominent for lymph node–negative patients who received no chemotherapy. Background We aimed to investigate the prognostic influence of primary tumor site on the survival of patients with breast cancer. Patients and Methods Data of 63,388 patients with primary breast cancer from the Korean Breast Cancer Registry were analyzed. Primary tumor sites were classified into 5 groups: upper outer quadrant, lower outer quadrant, upper inner quadrant, lower inner quadrant (LIQ), and central portion. We analyzed overall survival (OS) and breast cancer–specific survival (BCSS) according to primary tumor site. Results Central portion and LIQ showed lower survival rates regarding both OS and BCSS compared with the other 3 quadrants (all P < .05) and hazard ratios were 1.267 (95% CI, 1.180-1.360, P < .001) and 1.215 (95% CI, 1.097-1.345, P < .001), respectively. Although central portion showed more unfavorable clinicopathologic features, LIQ showed more favorable features than the other 3 quadrants. Primary tumor site was a significant factor in univariate and multivariate analyses for OS and BCSS (all P < .001). For lymph node–negative patients, LIQ showed a worse OS than the other primary tumor sites in the subgroup with no chemotherapy (P < .001), but that effect disappeared in the subgroup with chemotherapy (P = .058). Conclusion LIQ showed a worse prognosis despite having more favorable clinicopathologic features than other tumor locations and it was more prominent for lymph node–negative patients who received no chemotherapy. The hypothesis of possible hidden internal mammary node metastasis could be suggested to play a key role in LIQ lesions.
All Science Journal Classification (ASJC) codes
- Cancer Research